| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/07/2013 | CA2681712C Tamibarotene capsule preparation |
| 05/07/2013 | CA2572555C Fusion protein of porcine reproductive and respiratory syndrome virus as prrs vaccine |
| 05/07/2013 | CA2558029C Ion binding polymers and uses thereof |
| 05/07/2013 | CA2531566C Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 05/07/2013 | CA2530645C Dosage form |
| 05/07/2013 | CA2530363C Carrier proteins for vaccines |
| 05/07/2013 | CA2496376C Methods of drug delivery using sulphated chitinous polymers |
| 05/07/2013 | CA2467053C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/02/2013 | WO2013063527A1 Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d |
| 05/02/2013 | WO2013063510A1 Protein formulations containing amino acids |
| 05/02/2013 | WO2013063286A1 Treatment of patients suffering from cancer |
| 05/02/2013 | WO2013062497A1 Liquid pharmaceutical formulations |
| 05/02/2013 | WO2013062441A1 Pharmaceutical combination of atorvastatin and nicergoline for the prophylaxis or treatment of disorders of the cerebral circulation |
| 05/02/2013 | WO2013062424A1 Method and composition for the treatment of pain and/or inflammation |
| 05/02/2013 | WO2013062073A1 Orally disintegrating tablet containing low-dose ramosetron |
| 05/02/2013 | WO2013062050A1 Aqueous gemcitabine solution preparation |
| 05/02/2013 | WO2013061969A1 Oxybutynin-containing transdermal absorption preparation |
| 05/02/2013 | WO2013061818A1 Novel peptide complex and hybrid complex thereof, and use of said hybrid complex |
| 05/02/2013 | WO2013061588A1 Transdermally absorbed preparation |
| 05/02/2013 | WO2013060936A1 Aqueous antimicrobial composition containing coniferous resin acids |
| 05/02/2013 | WO2013060919A1 Controlled synthesis of polyglutamates with low polydispersity and versatile architectures |
| 05/02/2013 | WO2013060770A1 Hemostatic compositions |
| 05/02/2013 | WO2013060303A1 Polypeptides inhibiting neovascularization and uses thereof |
| 05/02/2013 | WO2013060261A1 Block copolymer, liquid composite thereof, nucleic acid preparation, preparation methods therefor, and use thereof |
| 05/02/2013 | WO2013060052A1 Hypoallergenic recombinant immunotoxin, and preparation method and application thereof |
| 05/02/2013 | WO2013059922A1 Limit size lipid nanoparticles and related methods |
| 05/02/2013 | WO2013040295A3 Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| 05/02/2013 | WO2013036850A3 Modulation of midbody derivatives |
| 05/02/2013 | WO2013036082A3 Polymeric compound to which tris(2-carboxyethyl) phosphine is bonded |
| 05/02/2013 | WO2013020040A3 Radiated cancer cells as a vehicle for cancer nanotherapy |
| 05/02/2013 | WO2013004234A3 Methods for producing liposomes |
| 05/02/2013 | WO2013003827A3 Macrogol 15 hydroxystearate formulations |
| 05/02/2013 | WO2012173392A9 Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection |
| 05/02/2013 | WO2012169735A9 Complex comprising water-soluble fragments of fcεri and composition comprising same for treating allergic diseases mediated by ige |
| 05/02/2013 | WO2012163827A3 Ophthalmic preparation comprising a pgf2alpha analogue |
| 05/02/2013 | WO2012031515A3 Low-modification biocompatible high polymer sulfhydryl-modified derivatives, cross-linked material thereof, and uses of said material |
| 05/02/2013 | WO2003047632A9 Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| 05/02/2013 | US20130110066 Foam and Delivery System for Treatment of Postpartum Hemorrhage |
| 05/02/2013 | US20130109756 Dual Drug Delivery Using Silicone Gels |
| 05/02/2013 | US20130109747 Pharmaceutical formulation |
| 05/02/2013 | US20130109743 Nucleic acid delivery composition and carrier composition, pharmaceutical composition using the same, and method for delivering nucleic acid |
| 05/02/2013 | US20130109659 Pharmaceutical compositions of co-crystals of tramadol and coxibs |
| 05/02/2013 | US20130108737 Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| 05/02/2013 | US20130108708 Dental composites comprising nanoparticles of amorphous calcium phosphate |
| 05/02/2013 | US20130108707 In situ film-forming bioactive solutions of absorbable multiblock copolymers |
| 05/02/2013 | US20130108692 Compositions and methods for treating influenza |
| 05/02/2013 | US20130108685 Cationic lipid |
| 05/02/2013 | US20130108681 Injectable Depot Compositions and Uses Thereof |
| 05/02/2013 | US20130108675 Organic compounds |
| 05/02/2013 | US20130108674 Ophthalmic compositions for the administration of liposoluble active ingredients |
| 05/02/2013 | US20130108648 Nanoparticulate in-situ gels as vitreous humor substitutes for ocular diseases |
| 05/02/2013 | US20130108620 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 05/02/2013 | US20130108581 Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic Agents |
| 05/02/2013 | US20130108557 Cosmetic foam |
| 05/02/2013 | US20130108548 Peptide derivatives, preparation and uses thereof |
| 05/02/2013 | CA2856608A1 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof |
| 05/02/2013 | CA2853823A1 Protein formulations containing amino acids |
| 05/02/2013 | CA2853705A1 Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
| 05/02/2013 | CA2853356A1 Hemostatic compositions |
| 05/02/2013 | CA2853316A1 Limit size lipid nanoparticles and related methods |
| 05/02/2013 | CA2853112A1 Antibody formulations and methods |
| 05/02/2013 | CA2853100A1 Compositions and methods for treatment of proteinopathies |
| 05/02/2013 | CA2850908A1 Aqueous antimicrobial composition containing coniferous resin acids |
| 05/02/2013 | CA2850034A1 Therapeutic combinations and methods of treating melanoma |
| 05/01/2013 | EP2586811A1 Branched hetero-polyethylene glycol and intermediate |
| 05/01/2013 | EP2586523A1 Process for producing emulsifier-producing material, process for producing emulsifier, emulsifier for orally administered composition, and orally administered composition |
| 05/01/2013 | EP2586464A1 Tolvaptan solid dispersion and its preparation method |
| 05/01/2013 | EP2586463A1 Pharmaceutical multimeric particles, and manufacturing method for same |
| 05/01/2013 | EP2586459A1 VEGF antagonist formulations |
| 05/01/2013 | EP2586447A1 Heterochain aliphatic poly-n-oxide copolymers and vaccinating agents and drugs based thereon |
| 05/01/2013 | EP2586426A1 Carboxyvinyl polymer-containing nanoparticle suspensions |
| 05/01/2013 | EP2585504A1 Novel thickening polymer for ionic oil phases free of monomers |
| 05/01/2013 | EP2585114A2 Therapeutic conjugates of a dextrin polymer and an antimicrobial peptide |
| 05/01/2013 | EP2585113A1 Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| 05/01/2013 | EP2585098A1 Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same |
| 05/01/2013 | EP2585092A1 Pharmaceutical composition containing goserelin for in-situ implant |
| 05/01/2013 | EP2585091A1 Sustained-release formulation |
| 05/01/2013 | EP2585075A2 Methods of treatment for esophageal inflammation |
| 05/01/2013 | EP2585062A1 Injectable formulation of a macrocyclic lactone and levamisole |
| 05/01/2013 | EP2585060A1 Stimulating immune response |
| 05/01/2013 | EP2585046A2 Lecithin carrier vesicles and methods of making the same |
| 05/01/2013 | EP2585044A1 Long-term storage of non-glycosylated recombinant human g-csf |
| 05/01/2013 | EP2585041A1 Taste-masked pharmaceutical formulation having accelerated onset of action |
| 05/01/2013 | EP2585040A1 Compositions and methods for enhancing reduction of spore-forming microorganism |
| 05/01/2013 | EP2585038A1 Pharmaceutical composition comprising midazolam |
| 05/01/2013 | EP2585037A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 05/01/2013 | EP2584900A1 Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis |
| 05/01/2013 | CN103080204A Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
| 05/01/2013 | CN103080159A Novel thickening polymer for ionic oil phases free of monomers |
| 05/01/2013 | CN103080125A Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| 05/01/2013 | CN103079597A Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
| 05/01/2013 | CN103079596A Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation |
| 05/01/2013 | CN103079595A Aqueous composition for ophthalmic administration |
| 05/01/2013 | CN103079592A Method for treating and diagnosing cancer by using cell-derived microvesicles |
| 05/01/2013 | CN103079559A Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| 05/01/2013 | CN103079552A Topical pharmaceutical composition comprising flurbiprofen |
| 05/01/2013 | CN103079547A Process for producing drug-block-copolymer composite and pharmaceutical product containing same |
| 05/01/2013 | CN103079545A Sulforaphane stabilization |
| 05/01/2013 | CN103079544A Injectable flowable composition comprising buprenorphine |
| 05/01/2013 | CN103079543A Ophthalmic compositions for the administration of liposoluble acitve ingredients |